A terminator-inspired liquid metal stent for treating atherosclerotic vascular stenosis with precise vascular matching and magnetothermally regulated active degradation Authors: Jianxiang Xiong, Li Huang, Jingzheng Huang, Zhibin Zhou, Shen Hu, Wenpeng Zhao, Guizhen Xu, Xingchun Lai, Guoyu Yang, Weimin Zhou, Xiaolei Wang Published: 2026 ABSTRACT AbstractAtherosclerosis represents the primary pathological basis of cardiovascular diseases. Vascular stent implantation as a key intervention for treating atherosclerosis, currently faces challenges such as the lack of personalized customization, difficulty in precisely matching diseased vessels, and prolonged risks of thrombosis and restenosis. Inspired by the shape-shifting liquid-metal robot T-1000 from the film Terminator, this research pioneers the use of liquid metal (LM) in vascular interventional therapy. LM was cast into a mold, then drilled and ground to the Hep/PLL/PDA/LM stent. Its heparin coating confers effective anti-thrombogenic activity and mitigates restenosis. More importantly, after the process of vascular remodeling, the stent can be degraded non-invasively through the application of an alternating magnetic field. Furthermore, the stent material exhibits notable antioxidant and anti-inflammatory properties. The findings above suggest that the magnetothermal characteristics of LM make it possible to precisely match diseased vessels and achieve controllably degradable vascular interventional therapy. This capability can fundamentally address the safety risks associated with the prolonged presence of traditional vascular stents, potentially eliminating the necessity for follow-up surgical interventions.Keywords: Liquid metal stent, Magnetothermal, Non-invasive degradation, Heparin coating, Atherosclerotic vascular stenosis Introduction As the leading cause of death worldwide, cardiovascular disease (CVD) accounts for about 18 million deaths annually, representing 32% of global mortality [1,2]. Atherosclerosis (AS) constitutes the primary pathological basis of CVD, which may subsequently trigger acute cardiovascular and cerebrovascular events such as myocardial infarction, coronary heart disease, carotid stenosis, and stroke [3,4]. The main clinical treatment for AS is interventional surgery, which involves implanting stents to support stenotic or occluded blood vessels [5]. However, conventional stent therapy is hindered by three major constraints: Firstly, clinically available stents are mass-produced and fail to provide an anatomical precision fit for the unique vasculature of individual patients [6]. Secondly, most currently used stents are non-degradable and remain in the body as permanent foreign materials [7]. This can result in vascular injury and complications such as immune rejection, thrombosis, and restenosis [8]. Patients often require prolonged administration of immunosuppressive and antithrombotic medications to mitigate these risks, which not only increases physiological burden but may also lead to additional adverse effects [9]. Thirdly, although research on biodegradable vascular stents has been conducted, precise control over the degradation process remains suboptimal [10]. Excessively rapid degradation can compromise mechanical integrity prematurely, leading to inadequate radial strength and, consequently, failure to achieve sustained vessel remodeling. In theory, the ideal vascular stent should possess the following three major characteristics (Scheme 1A): (1) It should allow for rapid and precise individualized customization based on the specific anatomical and pathological features of the diseased vessel. (2) It should exhibit mechanical properties comparable to those of conventional stents, providing sufficient radial strength to support and remodel the vascular lumen effectively. (3) Upon completion of vascular repair, the stent should safely degrade under non-invasive and controllable manners. Schematic illustration of the fabrication process of Hep/PLL/PDA/LM and mechanism for treating atherosclerotic vascular stenosis. A) Core design and advantages of Hep/PLL/PDA/LM: Ⅰ) Based on clinical imaging data, personalized customization; Ⅱ) Excellent mechanical support properties, effectively scaffolding the vessel upon implantation to restore blood flow and intervene in the atherosclerotic progression; Ⅲ) Non-invasively and actively controllable on-demand degradation. B) LM robot solid-liquid phase transition process. C) Synthesis process of Hep/PLL/PDA/LM. D) Implantation of Hep/PLL/PDA/LM into the rabbit carotid artery model can eliminate ROS in the atherosclerotic microenvironment, suppress inflammation, attenuate plaques, and enable controlled non-invasive degradation. Underlying mechanisms are as follows: Ⅰ) Inhibiting red blood cells and platelets adhesion to exert anti-thrombogenic effects; Ⅱ) Specifically inhibiting the proliferation and migration of smooth muscle cells to prevent restenosis; Ⅲ) Improving the local inflammatory microenvironment by scavenging excess intracellular NO and regulating macrophage polarization, thereby exerting anti-inflammatory effects; Ⅳ) Controllable and non-invasive degradation under an external alternating magnetic field. Ⅴ) Achieving vascular remodeling. The liquid-metal (LM) robot T-1000 in the film Terminator possesses exceptional solid-liquid phase transition capability (Scheme 1B), enabling it to reconfigure its shape in response to combat needs dynamically. Inspired by this, this research explored the feasibility of applying such phase-transitional LMs to fabricate vascular stents. LMs primarily refer to an emerging class of biomaterials composed of gallium (Ga) and gallium-based alloys (containing indium (In), tin (Sn), bismuth (Bi), zinc (Zn), etc.) [11], which exhibit both metallic properties and fluid-like behavior [12,13]. Among them, certain materials not only demonstrate favorable biocompatibility and low toxicity but can also undergo reversible solid-liquid phase transitions at relatively low temperatures under magnetothermal control [14]. Leveraging the aforementioned properties of LMs, our team designed and fabricated a novel vascular stent (Hep/PLL/PDA/LM) for the first time. This stent comprises an LM core coated with polydopamine (PDA) and further functionalized with a nanocoating of heparin (Hep) and poly-L-lysine (PLL), which provides anticoagulant and anti-thrombogenic functions (Scheme 1C). This design offers three key advantages (Scheme 1A): First, by utilizing clinical imaging data, we can melt LM and fabricate it so that it precisely matches the diseased vessel, enabling accurate interventional therapy. Second, the stent demonstrates favorable biosafety and sufficient mechanical strength, allowing effective vessel dilation and lumen patency maintenance after implantation, thereby facilitating vascular remodeling. Third, and the most importantly, after vascular functional recovery, the stent can be non-invasively degraded through active external control without requiring secondary surgical extraction. This approach can not only address the safety risks associated with prolonged stent retention but also prevent the need for repeat surgery. Taking the carotid artery model as an example (Scheme 1D), this stent not only reduces reactive oxygen species (ROS) levels within the vascular microenvironment and alleviates oxidative stress, but also suppresses the expression of monocyte chemotactic protein-1 (MCP-1), cluster of differentiation 14 (CD14), α-smooth muscle actin (α-SMA), and proliferating cell nuclear antigen (PCNA), thereby achieving effective treatment of AS. Furthermore, both the Hep coating and the stent exert multiple synergistic functions: Ⅰ) The Hep coating provides potent anticoagulant activity, effectively inhibiting blood cell adhesion and thrombosis without impairing the function of normal endothelial cells (ECs). Ⅱ) Hep specifically suppresses the proliferation and migration of vascular smooth muscle cells (VSMCs), contributing to the prevention of restenosis. Ⅲ) The LM core itself possesses intrinsic anti-inflammatory properties. It can scavenge redundant intracellular nitric oxide (NO) by inhibiting inducible nitric oxide synthase (iNOS) and promoting arginase-1 (Arg-1) expression. This action inhibits macrophage polarization toward the pro-inflammatory M1 phenotype while promoting the anti-inflammatory M2 phenotype, downregulates the expression of inflammatory cytokines interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α), and upregulates the expression of anti-inflammatory cytokines interleukin-4 (IL-4) and interleukin-10 (IL-10). Ⅳ) Once vascular remodeling is complete, the stent can be actively and non-invasively degraded through external application of the alternating magnetic field. Ⅴ) Following vascular recanalization, the degradation products can be safely metabolized and eliminated from the body, thereby eliminating the prolonged risks associated with permanent stent retention. Materials and methods Materials Ga (99.99%), In (99.99%), Sn (99.99%), and Bi (99.99%) were purchased from Hebei Hangba Metal Materials Co., Ltd. Heparin sodium, Dopamine hydrochloride, poly-L-lysine (MW 150‒300 kDa), Toluidine Blue-O, and 4′,6-diamino-2-phenylindole (DAPI) were purchased from Aladdin Reagents of China. Activated partial thromboplastin time (APTT) assay kit, thrombin time (TT) assay kit, 2.5% glutaraldehyde electron microscope fixation solution, Cell Counting Kit-8 (CCK-8) assay kit, calcein acetoxymethyl ester/propidium iodide (Calcein-AM/PI) cell staining kit, ROS assay kit, and NO assay kit were all purchased from Solarbio Science & Technology Co., Ltd. (Beijing, China). 3% bovine serum albumin, 4% paraformaldehyde solution, and the BCA protein quantification kit were procured from Wuhan Servicebio Technology Co., Ltd. In addition, the following antibodies were acquired: anti-iNOS monoclonal antibody (BA0362, BOSTER), anti-Arg-1 monoclonal antibody (A01106, BOSTER), and anti-β-actin monoclonal antibody (BA2305, BOSTER). Human umbilical vein endothelial cells (HUVECs), mouse leukaemic monocyte macrophage-like cells (RAW264.7), and VSMCs were provided by the Institute of Translational Medicine, Nanchang University. The 2.0 mm balloon catheter (APT Medical Co., Ltd.) and contrast agent (350 mg L−1, GE CO., USA) were supplied by the Second Affiliated Hospital of Nanchang University. Unless otherwise noted, all other reagents were obtained from commercial sources and used as received. Synthesis of LM Ga, In, Sn, and Bi were weighed at a mass ratio of 2.8:3.5:3:3, melted at high temperature, and mixed homogeneously. After 2 min, the mixture was quenched in cold water. This heating and quenching cycle was repeated 3 times. The resulting material was then rapidly cooled in a −80°C freezer to prepare the LM alloy for storage and future use. For in vitro magnetothermal degradation testing, the LM in its molten state was poured into a mold, followed by drilling and polishing to fabricate the simplified stent. Preparation of Hep/PLL/PDA/LM Different concentrations of Hep solution were added to an equal volume of 0.5 mg mL−1 PLL solution and sonicated for 5 min to obtain Hep/PLL nanoparticles at concentrations of 0.1, 0.2, 0.3, 0.4, 0.5, 1, 1.5, and 2.0 mg mL−1. Subsequently, dopamine hydrochloride was dissolved in Tris buffer to prepare PDA solutions with concentrations of 0.5, 0.75, 1.25, 1.5, 1.75, and 2 mg mL−1. LM samples were cleaned by sonication for 5 min and then immersed in the above PDA solutions, followed by stirring in the dark at room temperature for 24 h. The samples were then ultrasonically cleaned with ultrapure water for 5 min to obtain PDA/LM. The PDA/LM samples were immersed in Hep/PLL solution, stirred in the dark at room temperature for 24 h, and finally ultrasonically cleaned with ultrapure water for 5 min to obtain Hep/PLL/PDA/LM. Quantification of Hep and drug release The Hep content in the samples was measured using the toluidine blue-O method [15]. Briefly, standard Hep solutions were prepared in PBS buffer (10 mM, pH 7.4) at concentrations of 0, 2, 4, 8, 16, 32, 64, and 128 μg mL−1. To establish a standard curve relating Hep concentration to absorbance, the test samples were immersed in a solution containing 5 ml of toluidine blue-O solution and 5 ml of PBS buffer, followed by shaking for 2 h. Next, 10 ml of n-hexane was added, and the mixture was shaken for an additional 5 min. After removing the samples, the absorbance of the aqueous phase was measured at 630 nm using a UV-vis spectrophotometer, with PBS buffer as the reference. The Hep concentration in the test samples was then determined by comparing the absorbance of the aqueous phase with the standard Hep curve. Using the above method, the appropriate concentrations of Hep/PLL and PDA were determined. For the Hep release assay, Hep/PLL/PDA/LM samples were placed in PBS and stored at room temperature, and the Hep content in the solution was measured every 3 days. Hemolysis test Fresh rabbit blood was collected, washed, and the red blood cells (RBC) were isolated. The positive control was prepared by mixing 1.1 mL of deionized water with 0.1 mL of the RBC suspension, while the negative control consisted of 1.1 mL of physiological saline mixed with 0.1 mL of the RBC suspension. For the experimental groups, 0.1 mL of RBC was mixed with 1.1 mL of the respective extraction medium: LM, PDA/LM, or Hep/PLL/PDA/LM (prepared by immersing 1 g of each material in 0.9% NaCl for 72 h as the extraction medium). After incubation at 37°C for 2 h, the mixtures were centrifuged, and 0.1 mL of the supernatant was collected. The absorbance at 540 nm was measured using a microplate reader. The hemolysis rate (%) was calculated using the following formula: OD0 represents the absorbance of the experimental group, OD1 is the absorbance of the negative control, and OD2 is the absorbance of the positive control. Water contact angle Samples of LM, PDA/LM, and Hep/PLL/PDA/LM were placed horizontally on the measurement stage. The water contact angle was measured using a contact angle goniometer (DSA100, KRÜSS, Germany). APTT and TT assays Platelet-poor plasma was prepared by centrifuging fresh human whole blood at 3000 rpm for 10 min. Samples (5 mm3 of LM, 5 mm3 of PDA/LM, and 5 mm3 of Hep/PLL/PDA/LM; unless otherwise specified, all subsequent experiments used these sample dimensions) were incubated with 0.5 mL of PPP at 37°C for 1 h. APTT and TT were then measured using the respective assay kits. Blood cell adhesion test Fresh rabbit blood was centrifuged at 1500 rpm for 10min to obtain PRP and hemocyte precipitate, respectively. 50 mL of PRP and hemocyte precipitate, were applied to the sample surface, incubated at 37°C for 1 h, and then rinsed with PBS. The samples were fixed in 2.5% glutaraldehyde for 4 h, followed by gradient dehydration with ethanol for 30 min. After air drying, the samples were imaged using SEM. 50 μL PRP was dropped on the samples, incubated at 37°C for 1 h, and washed 3 times with PBS. Then, stained with rhodamine B for 20 min, washed 3 times with PBS, and air-dried for fluorescence photography. Melting point determination of Hep/PLL/PDA/LM Samples were evenly distributed in a crucible. An empty crucible was used as a reference. Both crucibles were placed inside the sample chamber of a Differential Scanning Calorimeter (DSC, TA Instruments). The DSC scan was initiated, and the real-time heat flow curve was recorded. Mechanical property testing Samples were positioned between two plates of a universal testing machine (UTM2203, SUNS, China). They were compressed at a rate of 2 mm min−1 until fracture, with 3 parallel samples tested per group. For tensile testing, the ends of the samples were fixed with clamps and stretched at a rate of 1 mm min−1 until fracture, with 3 parallel samples per group. The Young's modulus was calculated accordingly [16]. Magnetothermal response and in vitro degradation The heating performance of LM samples with varying masses, as well as equal masses of LM, PDA/LM, and Hep/PLL/PDA/LM, was evaluated under an alternating magnetic field (813 Oe, 430 kHz (1 Oe = 79.5775 A m−1)) using a magnetothermal therapy analyzer (HYPER-4MSI, USA). Temperature changes were recorded via OptiLink software. Hep/PLL/PDA/LM stents (3 stents per group) were immersed in PBS, and photographs (Nikon B600, Japan) were taken at 0, 1, 2, and 3 months to monitor degradation. The release of Ga3+ was measured by ICP-OES. For real-time thermal monitoring, a simplified Hep/PLL/PDA/LM stent was placed in PBS at 37°C under an alternating magnetic field (636 Oe, 157 kHz), and temperature changes were observed and recorded using an infrared thermal imager (E60, FLIR). A rabbit carotid artery flow-mimicking model was constructed using a glass groove to simulate the vessel and PBS at 37°C flowing at 15 cm s−1 to simulate blood flow. The simplified stent was placed in this setup, and its degradation was observed after applying the alternating magnetic field. In vitro cytotoxicity The CCK-8 assay was performed to evaluate cytotoxicity. Cells were seeded at a density of 5000 cells per well in 96-well plates. After cell attachment, the medium in the control group was replaced with 100 μL of fresh culture medium, while the experimental groups received 100 μL of sample extracts (standard extracts: sterilized samples of LM, PDA/LM, and Hep/PLL/PDA/LM (1 g each) were immersed in 1 mL of complete culture medium and incubated under standard cell culture conditions (37°C, 5% CO2, >95% humidity) for 7 days; unless otherwise specified, all subsequent experiments used these standard extracts solution). Following incubation for 1, 2, and 3 days, 10 μL of CCK-8 reagent was added to each well, and the plates were incubated for an additional 2 h in the dark. Absorbance at 450 nm was measured using a microplate reader. Cell viability was calculated using the following formula: AS represents the absorbance of the experimental group, AP is the absorbance of the blank control, and AC is the absorbance of the negative control (cells without treatment). Short-term cell adhesion assay HUVECs and VSMCs were seeded in 6-well plates at a density of 1 × 105 cells per well and co-cultured with the samples. After 6 h, cell adhesion was observed under a microscope. Non-adherent cells were removed by washing with PBS, followed by trypsinization and counting of the adherent cells. The number of adherent cells in each group was calculated to evaluate the effect of the materials on the short-term adhesion ability of both cell types. Live/dead cell staining HUVECs and VSMCs were seeded in 6-well plates using the method described above. The cells were then co-cultured with the samples (unless otherwise specified, the same protocol was applied in subsequent experimental groups). After 24 h, the culture medium was removed, and non-adherent cells were washed away with PBS. Live/dead cell staining was performed using a Calcein-AM/PI staining kit, and the results were observed under a fluorescence microscope. Cell proliferation For the colony formation assay, HUVECs and VSMCs were seeded in 6-well plates at a density of 200 cells per well. After 24 h of attachment, the cells were co-cultured with the samples. Cell colony formation was observed under a microscope at intervals of 2 to 3 days. When most clones contained more than 50 cells, the culture was terminated. The cells were washed 3 times with PBS, fixed with 4% paraformaldehyde for 30 min, washed 3 times again with PBS, stained with 0.1% crystal violet for 15 min, washed three times with PBS, air-dried in a ventilated area, and photographed to observe colony formation in each group. For the cell counting assay, HUVECs and VSMCs were seeded in 6-well plates and co-cultured with the respective materials in the experimental groups. Cell counts were performed on days 2, 4, and 6, and proliferation curves were plotted. Cell migration ability Scratch Assay: HUVECs and VSMCs were seeded in 6-well plates at a density of 1 × 105 cells per well. When cell confluence exceeded 90%, a straight scratch was made vertically down the center of each well using a 200 μL sterile pipette tip. The wells were gently washed with 1 mL PBS. The control group received 2 mL serum-free medium, while the experimental groups were co-cultured with the samples. Images were taken under a microscope at 0 h, 12 h, 24 h, and 48 h. Transwell Assay: HUVECs and VSMCs in the logarithmic growth phase were seeded at 7000 cells per well into the upper chambers of transwell inserts. The lower chamber of the 24-well plate for the control group contained medium with 20% FBS and 1% penicillin-streptomycin. For the experimental groups, 650 μL of sample extract (prepared using the same medium as the extraction medium) was added to the lower chamber, ensuring that the membrane at the bottom of the insert was fully immersed. After 12 h of incubation, the inserts were washed with PBS, fixed with 4% paraformaldehyde for 30 min, washed 3 times with PBS, stained with 0.1% crystal violet, air-dried, and then observed and photographed under a microscope. ROS scavenging assay RAW264.7 were seeded in 6-well plates at a density of 5 × 104 cells per well. After 24 h of culture, 1 mM hydrogen peroxide was added to each well. The experimental groups were co-cultured with the samples, while the control group received no further treatment. After 4 h, 2′,7′-dihydrodichlorofluorescein diacetate (DCFH-DA) was added as a fluorescent ROS probe along with a nuclear dye to detect intracellular ROS levels. Following incubation in the dark for 30 min, the cells were observed, and fluorescence images were captured using an inverted fluorescence microscope. The fluorescence intensity was quantified using ImageJ software (NIH, USA), and the ROS scavenging rate was calculated relative to the positive control group. NO scavenging assay NO levels were detected using 4,5-diaminofluorescein diacetate (DAF-2DA) as a fluorescent probe. Briefly, RAW264.7 cells were seeded in 6-well plates at a density of 5 × 104 cells per well. After 24 h of culture, LPS was added to each well at a concentration of 10 μg mL−1. The experimental groups were co-cultured with the samples, while the control group received no further treatment. Following 24 h of incubation, DAF-2DA was added, and the plates were incubated in the dark for 30 min. Fluorescence images were then observed and captured using an inverted fluorescence microscope. Western blot RAW264.7 were stimulated with LPS under the same treatment conditions described above. After treatment, the cells were collected, and total protein was extracted using RIPA lysis buffer (BL 504 A, Biosharp) supplemented with protease and phosphatase inhibitors. Protein concentration was determined with a BCA assay kit. The proteins were then separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto a polyvinylidene fluoride membrane (IPVH 00010, Millipore). The membrane was blocked with 5% bovine serum albumin for 1 h, incubated with primary antibody at 4°C overnight, washed, and then incubated with secondary antibody for 1 h. Protein bands were detected using an Image Quant system (LAS 500) and quantified with ImageJ software. Macrophage polarization Sterile cell slides were placed in 6-well plates at a density of 1 × 105 cells per well. Unpolarized RAW264.7 were seeded and then treated with 10 μg mL−1 LPS. The control group received no further treatment, while the experimental groups were co-cultured with the samples for 24 h. The slides were removed, washed 3 times with PBS, and fixed with 4% paraformaldehyde for 20 min. Permeabilization buffer was added and incubated for 20 min, followed by three washes with PBS. The slides were blocked with 3% bovine serum albumin for 30 min, washed 3 times with PBS, and incubated with primary antibody at 4°C overnight. After incubation with the corresponding secondary antibody at room temperature for 50 min, nuclei were stained with DAPI. Results were observed by flow cytometry (Sysmex, CyFlow Cube 8) and fluorescence microscopy. RT-qPCR Briefly, RAW264.7 were seeded in 6-well plates and induced with LPS for 8 h. The cells were then treated with the corresponding materials for an additional 24 h. Total RNA was extracted according to the instructions of the RNA isolation kit, followed by reverse transcription. The resulting cDNA was used for quantitative polymerase chain reaction to evaluate the mRNA levels of IL-1β, TNF-α, IL-4, and IL-10. The primer sequences used are listed in Table S1. Establishment of animal models To establish a model of carotid atherosclerotic stenosis, New Zealand White rabbits (5 months, female, 2.5 kg body weight) were anesthetized. The right common carotid artery (RCCA) was exposed under microscopy and incised. Endothelial injury was induced by repeated balloon angioplasty using a 2 mm-diameter balloon to denude the intima. The rabbits were then fed a high-fat diet for 2 months. Carotid color Doppler ultrasound and CTA were subsequently performed to confirm significant stenosis of the RCCA (vessel diameter < 50%). Thereafter, the body weight of the rabbits was monitored every 3 months. In vivo treatment Rabbits in the control and model groups received no intervention. After successful anesthesia, rabbits in the experimental group underwent implantation of the Hep/PLL/PDA/LM vascular stent at the stenotic site of the RCCA. 3 months post-treatment, the rabbits in the experimental group were placed under an alternating magnetic field to initiate stent degradation. Color Doppler ultrasound Carotid artery ultrasound was performed after 2 months of high-fat diet feeding and following magnetothermal stent degradation. The neck region of the rabbits was shaved, and after induction of inhalation anesthesia, the examination was conducted along the carotid artery using the ultrasound diagnostic system (VINNO6, Feinuo Technology Co., Ltd., China). CTA examinations CTA was performed before Hep/PLL/PDA/LM stent implantation, after stent implantation, and following magnetothermal degradation of the stent. Iohexol injection (Omnipaque, diluted to 200 mg mL−1, total dose 8.0 mL per rabbit) was administered via a high-pressure injector connected to the marginal ear vein at an injection rate of 0.5 mL s−1. Scanning parameters on a 256-slice spiral CT scanner (IQon Spectral CT, Philips, the Netherlands) were set at 120 kV, 100 mAs, slice thickness of 5 mm, delay time of 2 s, and scan duration of 30 s. Results were evaluated using vascular assessment software (IntelliSpace Portal, Philips) on the CT workstation. Whole-body X-ray scanning was performed 3 months after the stent degradation. Magnetothermal in vivo degradation 3 months after implantation of the Hep/PLL/PDA/LM vascular stent, anesthetized rabbits from the experimental group were placed within an alternating magnetic field (636 Oe, 157 kHz). Temperature changes in the rabbit's neck region were monitored and recorded using an infrared thermal imager. Vascular histological staining Carotid arteries from each group were rinsed and fixed with 4% paraformaldehyde, then embedded and sectioned into 4 μm slices. The sections were subjected to H&E and Masson staining, followed by histopathological and morphological analysis under a microscope. Changes in intimal thickness and lumen diameter were quantified using ImageJ software. Immunofluorescence staining was performed to detect the expression of cluster of differentiation 31 (CD31). Immunofluorescence. Immunohistochemistry (IHC) staining was performed to detect the expression of heat shock protein 70 (HSP70), MCP-1, CD14, α-SMA, and PCNA in the carotid arteries of each group. After antigen retrieval, the sections were incubated with primary and secondary antibodies, stained, and observed under a microscope. The average optical density (AOD) of positively stained cells was measured and analyzed using ImageJ software. In vivo biosafety assessment After 3 months of in vivo treatment of carotid artery stenosis with the Hep/PLL/PDA/LM vascular stent, its degradation was initiated under the alternating magnetic field. Complete blood count and blood biochemistry panels were performed immediately after magnetothermal treatment and again 3 months post-degradation. Major organs were collected for H&E staining at both time points. Additionally, elemental analysis via ICP-OES was conducted 3 months after degradation to examine the accumulation of the material components. Statistical analysis All data were presented as mean ± standard deviation (s.d.). Statistical analysis was conducted using GraphPad Prism 9.4.1. Differences between groups were assessed by one-way ANOVA and unpaired t-test, and differences in the same group at different times were assessed by paired t-tests. “ns” indicates no statistical significance; a probability (p) value of < 0.05 was considered statistically significant (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001). Results Characterization of Hep/PLL/PDA/LM The LM was prepared by melting Ga, In, Sn, and Bi. To endow the material with anticoagulant and anti-thrombogenic capabilities, this research developed a PDA/LM, which was further modified with Hep [17]. The chemical formula of Hep is shown in Fig. S1. Since the native PDA coating provides insufficient amino groups for effective Hep conjugation [18], we introduced the cationic amino-rich polypeptide PLL. The negatively charged Hep forms Hep/PLL nanoparticles with PLL and is loaded onto the PDA/LM surface, culminating in the fabrication of the functionalized Hep/PLL/PDA/LM material [19]. As shown in Fig. 1A, the bare LM surface exhibited a silvery-white metallic luster with a relatively smooth surface under scanning electron microscopy (SEM). PDA/LM appeared gray-black due to the PDA coating, and SEM images showed the surface was covered with numerous particles approximately 450‒600 nm in size. Macroscopically, uniform coating traces were observed on the surface of Hep/PLL/PDA/LM, while SEM revealed a granular outer shell, with the outermost layer consisting of translucent particles approximately 350 nm in diameter. Energy dispersive spectroscopy (EDS) analysis of the elemental composition indicated the presence of Ga, In, Sn, Bi, and nitrogen (N) in Hep/PLL/PDA/LM, along with the characteristic sulfur (S) element of Hep (Fig. 1B). Synthesis and Characterization. A) Photographs and SEM images of LM, PDA/LM, and Hep/PLL/PDA/LM. B) EDS elemental analysis of Hep/PLL/PDA/LM. C) Particle size distribution of Hep/PLL at different concentrations. D) Zeta potential analysis of Hep/PLL at different concentrations. E) FTIR spectra of LM, PDA/LM, and Hep/PLL/PDA/LM. F-H) XPS spectra of LM, PDA/LM, and Hep/PLL/PDA/LM. Data are means ± s.d. (n ≥ 6). Particle size analysis of Hep/PLL at different Hep concentrations showed that the particle size decreased with increasing Hep concentration. (Fig. 1C). This can be explained by the evolving intermolecular interactions. At low Hep concentrations, weaker intermolecular forces resulted in loosely packed Hep/PLL with larger particle sizes. As the Hep concentration increased, the particles became more densely packed, leading to a corresponding reduction in size. Particle size plateaued when the Hep concentration exceeded 1 mg mL−1, indicating that Hep had reached saturation in the reaction system. Consistent with this observation, the zeta potential results in Fig. 1D showed a gradual increase in the negative surface charge of the particles as the Hep concentration was raised. Fourier-transform infrared spectroscopy (FTIR) was used to characterize the surface functional groups of the samples (Fig. 1E). A strong absorption band at 1600‒1550 cm−1, attributed to the overlapping C=C stretching and C=N stretching vibrations in PDA/LM and Hep/PLL/PDA/LM samples, confirmed the successful coating of PDA on the LM surface. Compared with the PDA/LM group, the Hep/PLL/PDA/LM group spectrum exhibited distinct changes: A broad band emerged around 1600‒1580 cm−1, corresponding to the superimposed signals from the asymmetric COO− stretching of Hep, the C=C/C=N vibrations of PDA, and the C=O stretching of PLL. A strong absorption peak at 1104 cm−1 was assigned to the overlapping C–O–C stretching and the symmetric S–O stretching of sulfonate groups in Hep, confirming the successful loading of Hep. Additionally, a medium-intensity absorption peak at 1385 cm−1, primarily assigned to the in-plane C–H bending of methylene groups, also contains a minor contribution from the in-plane S=O bending vibration of Hep sulfonate. This further supports the coexistence of an aliphatic alkyl backbone and Hep functional groups within the composite coating [20]. The material structure was further verified using X-ray photoelectron spectroscopy (XPS): The full XPS spectrum of the LM sample displayed characteristic peaks of Ga, In, Sn, and Bi (Fig. 1F). Characteristic peaks of carbon (C), N, and oxygen (O) corresponding to PDA were observed in PDA/LM (Fig. 1G). The absence of the S2p characteristic peak in Fig. 1H can likely be attributed to two factors: First, the binding energies of the S2p peak (168‒169 eV) overlap with the strong Bi4f signal (158‒164.5 eV), leading to potential masking of the sulfur signal; Second, the significantly higher concentration of bismuth in the sample, combined with the fact that the sensitivity factor of Bi is over ten times greater than that of S2p, makes sulfur detection challenging under the given experimental conditions. Anti-thrombogenic surface coating Hep in the solution was quantified using the toluidine blue-O method to determine the optimal Hep/PLL concentration (Fig. S2) [15]. The results showed that the Hep load gradually decreased when the concentration exceeded 1 mg mL−1 (Fig. 2A). This may be attributed to saturation of available amine groups and immobilized Hep/PLL on the surface at concentrations around 1.0 mg mL−1; further increases do not enhance effective loading. At higher concentrations, particle aggregation, steric hindrance, or a higher proportion of free Hep/PLL may also contribute. Therefore, 1 mg mL−1 Hep/PLL was finally selected for the subsequent coating fabrication. Similarly, we investigated the effect of different PDA concentrations on Hep loading, and the Hep loading was maximum when the PDA concentration was 1.5 mg mL−1. The reason may be that high PDA concentrations can induce aggregation on the material surface, reducing the effective contact area and consequently hindering the binding of drug molecules (Fig. 2B). The stability of the Hep coating is crucial for the safety and long-term anticoagulant efficacy of vascular grafts, as rapid release may trigger acute bleeding [21]. Release kinetics results (Fig. 2C) showed that Hep/PLL/PDA/LM exhibited a gradual Hep release during the initial period (first 15 days) of immersion in phosphate-buffered saline (PBS), and the release stabilized after 24 days. By day 30, the cumulative release amount was approximately 86 μg, and cumulative release reached approximately 97% (Fig. 2D). These findings demonstrate that the coating can achieve slow release of Hep, and has a long-term anticoagulant effect and safety in use. Evaluation of anticoagulant and anti-thrombogenic ability. A) Determination of the different concentrations of Hep/PLL. B) Determination of the different concentrations of PDA. C) Release characteristic of loaded Hep. D) Determination of Hep release rate. E) Hemolysis rate. F) Water contact angle. G) APTT determination Results. H) TT determination Results. I) SEM images of blood cell adhesion on LM, PDA/LM, and Hep/PLL/PDA/LM. J) Observation of platelet adhesion status by fluorescence microscopy. K) Observation of platelet adhesion status by SEM. Data are means ± s.d. (n ≥ 3). The p-values are shown above the bars, ns: not significant, ***p < 0.001, ****p < 0.0001. Good hemocompatibility is essential for blood-contacting implants to prevent thrombosis and ensure clinical success [22]. The hemolysis assay showed no hemolytic activity in LM, PDA/LM, or Hep/PLL/PDA/LM (Fig. 2E). The water contact angle test indicated that LM was mildly hydrophobic (contact angle > 100°). PDA coating reduced the contact angle, rendering the surface hydrophilic [23]. Further Hep/PLL modification continued this decreasing trend, significantly improving surface wettability and hemocompatibility [24], thereby improving anti-thrombogenic performance of the coating (Fig. 2F). Hep exerts its anticoagulant effect by specifically binding antithrombin Ⅲ and inhibiting coagulation factors Ⅹa and Ⅱa [25]. To evaluate the anti-thrombogenic capacity of the coatings, the activated partial APTT and TT were measured. Compared to normal plasma and PDA/LM, Hep/PLL/PDA/LM significantly prolonged both APTT (by ∼ 23 s) and TT (by ∼ 21 s), indicating substantially enhanced anticoagulant activity (Fig. 2G and H) [26]. The adhesion of blood cells on the material surfaces was observed by SEM (Fig. 2I): Pseudo-colored SEM images revealed that the surfaces of both LM and PDA/LM were covered with numerous discoid RBC and activated, pseudopodia-bearing platelets (PLT). In stark contrast, the Hep/PLL/PDA/LM surface showed a marked reduction in the number of both adherent RBC and PLT. In order to further observe the inhibition of platelet activation, platelet-rich plasma (PRP) was used for the reaction. Fig. 2J showed that the stent loaded with heparin can effectively inhibit PLT aggregation and adhesion. Subsequently, it was observed by SEM that the surfaces of the LM group and the PDA/LM group were covered with a substantial number of activated PLT, whereas no obvious PLT deposition was observed on the Hep/PLL/PDA/LM group (Fig. 2K). This result further confirms the excellent anticoagulant efficacy of Hep/PLL/PDA/LM in adequately inhibiting thrombosis. Scaffolding and in vitro magnetothermally degradation In addition to excellent anti-thrombogenic capacity, two core function of vascular stents is to provide: (1) reliable mechanical support after implantation; (2) and can to be safely removed after serving their purpose. Therefore, we systematically investigated the mechanical performance and unique magnetothermal-induced degradation behavior of Hep/PLL/PDA/LM. The Hep/PLL/PDA/LM vascular stent was fabricated by first preparing an LM-based stent, followed by surface modification with PDA and Hep/PLL nanocoating (Fig. 3A). Differential scanning calorimetry (DSC) revealed a melting point around 45°C (Fig. 3B). This melting point was chosen based on the resting body temperature (38.5‒39.5°C) of New Zealand white rabbits, which were used in subsequent animal studies. An excessively low melting point may result in insufficient mechanical strength of the stent in vivo, while a too high melting point may cause thermal damage to the vascular wall during the phase transition. To address these issues, the composition of Ga, In, Sn, and Bi was optimized to keep the melting point within an appropriate range while preserving favorable mechanical properties. In vitro degradation characteristics and magnetothermal properties of Hep/PLL/PDA/LM. A) Macroscopic appearance of the Hep/PLL/PDA/LM stent. B) The multiple phase transition processes of Hep/PLL/PDA/LM detected by DSC. C) In vitro sustained-release curve of Ga3+ during the degradation of Hep/PLL/PDA/LM. D) Degradation status of Hep/PLL/PDA/LM in PBS for 3 months. E) Dynamic process of heating-induced degradation of the stent under an alternating magnetic field. F) Magnetothermal degradation trend of Hep/PLL/PDA/LM under simulated rabbit carotid artery blood flow (flow velocity: 15 cm s−1). Data are means ± s.d. (n ≥ 6). Sufficient mechanical strength is essential for a stent to effectively dilate and support stenotic vessels, ensuring both procedural success and long-term patency [27]. The mechanical properties of the stent were evaluated by a material tensile test (Fig. S3). The Hep/PLL/PDA/LM stent exhibited a tensile strength close to 34 MPa, demonstrating excellent resistance to stretching. After being coated with PDA and Hep/PLL nanocoating, the tensile strain of the stent increased from 0.63% to 0.71%, while its Young's modulus showed no significant change. In terms of radial support, the maximum radial strength of Hep/PLL/PDA/LM exceeded 20 N mm−1, showing no significant difference compared to LM and PDA/LM. However, under high pressure, its diameter could be compressed from approximately 2.10 mm to about 1.62 mm before fracture, which was slightly greater than that of LM and PDA/LM. During long-term immersion in PBS, the stent's radial strength gradually decreased but remained about 18 N mm−1after three months. The release behavior of Gallium ions (Ga3+) from the stent was monitored by inductively coupled plasma optical emission spectroscopy (ICP-OES). It was found that Ga3+ release was relatively rapid during the first week of immersion in PBS, after which the release rate gradually slowed down (Fig. 3C). After three months of immersion, the stent showed no obvious signs of degradation (Fig. 3D), indicating good in vitro stability. The heating capability of LM under an alternating magnetic field is the basis for achieving the controllable phase transition. The magnetothermal performance results (Fig. S4) show that LM exhibits excellent heating capability, with a 50 mg sample heating over 40°C within 300 s. After coating with PDA and Hep/PLL nanocoating, the heating capability remained favorable. To validate the phase transition, a simple stent model (Fig. S5) was placed in PBS under an alternating magnetic field. Infrared thermography showed that the stent melted and collapsed after 45 s as its temperature rose from 27.3°C to 46.3°C (Fig. 3E). Subsequently, in order to observe the degradation of the stent during the solid-liquid phase transition, a model that could roughly simulate the blood flow state of the rabbit carotid artery was prepared (Fig. 3F). To avoid excessively rapid heating and melting, which could generate emboli, the magnetic field power was regulated to control the degradation rate. As shown in Fig. 3F, the stent gradually fragmented and slowly degraded under the impact of continuous water flow, and the carried-away fragments were smaller than 0.5 mm in diameter (Fig. S6). XPS analysis of the degradation products showed that there was no obvious change in the elemental composition of the Hep/PLL/PDA/LM (Fig. S7). In summary, the Hep/PLL/PDA/LM stent demonstrates favorable mechanical properties and can achieve rapid, controllable solid-liquid phase transition and degradation under an alternating magnetic field. This degradation process can be actively regulated by the external magnetic field, thereby effectively reducing the risk of vascular embolism caused by sudden melting of the stent. In vitro and in vivo safety experiments As an intravascular medical implant, the biocompatibility of vascular stents is the most important issue of clinical concern. To this end, we systematically evaluated the biocompatibility of the fabricated materials both in vitro and in vivo. LM, PDA/LM, and Hep/PLL/PDA/LM were co-cultured with HUVECs and VSMCs, respectively. CCK-8 assay results showed that none of the samples showed cytotoxicity to HUVECs (Fig. 4A). For VSMCs, cell viability in the Hep/PLL/PDA/LM group was partially inhibited on day 2 and day 3, but remained around 80% on day 3. The live/dead cell staining results further confirmed that the materials in each group had no significant toxicity to both cells (Fig. 4B and C). In addition, we conducted short-term cell adhesion activity testing, and the results suggested that LM, PDA/LM, and Hep/PLL/PDA/LM had no significant effect on the short-term adhesion activity of HUVECs and VSMCs (Fig. S8). In vitro and in vivo biosafety evaluation. A) Cell viability of HUVECs and VSMCs. B, C) Live/dead cell staining of HUVECs and VSMCs after 24 h co-culture with LM, PDA/LM, and Hep/PLL/PDA/LM. D) H&E staining of major organs from rabbits implanted with Hep/PLL/PDA/LM for 3 months and 6 months. E-G) Complete blood count. E) and blood biochemistry panels. F, G) before and after magnetothermal degradation of Hep/PLL/PDA/LM. Data are means ± s.d. (n ≥ 3). The p-values are shown above the bars, ns: not significant, *p < 0.05, **p < 0.01. Combined with the earlier hemocompatibility results (Fig. 2E), these findings demonstrate that Hep/PLL/PDA/LM possesses a favorable in vitro safety profile. For in vivo assessment, the stents were implanted into the rabbit carotid artery. Following a 3-month implantation period, degradation was triggered non-invasively via external application of an alternating magnetic field. The monitoring results showed no significant changes in body weight between the experimental and control groups at 3 months post-implantation or 3 months post-degradation (Fig. S9). No obvious pathological alterations were observed in hematoxylin and eosin (H&E) staining sections of major organs (Fig. 4D). Venous blood samples were collected immediately after stent degradation for complete blood count (Fig. 4E) and blood biochemistry panels (Fig. 4F and G). All measured representative parameters—including white blood cells (WBC), RBC, PLT, hemoglobin (HGB), alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), blood urea nitrogen (BUN), and creatinine (CREA)—showed no abnormalities. Concurrently, elemental accumulation in major organs and blood was assessed by ICP-OES. The results indicated that although the accumulation of Ga, In, Sn, and Bi in the liver, kidney, and blood in the treatment group was higher than control group, the total content of each element in the main organs and blood was low (Fig. S10) [28,29]. Based on the data reported in numerous experiments [[30], [31], [32], [33], [34]], the measured elemental levels were low in absolute terms, and no overt toxicity was detected by the evaluated endpoints. Follow-up blood analyses performed three months after degradation also showed no abnormalities (Fig. S11). Taken together, the in vitro and in vivo results demonstrate that the Hep/PLL/PDA/LM stent exhibits good biocompatibility. Hep/PLL/PDA/LM exerts an anti-restenotic effect by influencing cellular behaviors Having confirmed the excellent biocompatibility of the Hep/PLL/PDA/LM stent, we further investigated its cellular mechanisms for preventing restenosis. Endothelial dysfunction and extracellular matrix deposition are the primary pathological mechanisms leading to atherosclerotic vascular stenosis. Endothelial dysfunction not only contributes to chronic inflammation but may also induce thrombosis, whereas excessive extracellular matrix deposition results from the aberrant activation and proliferation of VSMCs [35]. We therefore assessed the effects of Hep/PLL/PDA/LM on the cellular behavior of HUVECs and VSMCs. CCK-8 proliferation assays revealed that LM, PDA/LM, and Hep/PLL/PDA/LM stents had no significant effect on the proliferation of HUVECs. In contrast, the Hep/PLL/PDA/LM coating significantly inhibited the proliferation of VSMCs from day 4 onward, with the effect becoming more pronounced by day 6 (Fig. S12). To further verify these observations, we performed colony formation assays. The results showed that there was no significant difference in the number of HUVEC colonies in LM, PDA/LM and Hep/PLL/PDA/LM groups compared with the control group (Fig. 5A–G); The number of VSMC colonies in LM group and PDA/LM group was also similar to that in the control group, while the number of VSMC colonies in the Hep/PLL/PDA/LM group was significantly reduced (Fig. 5B–H). These findings further confirmed that Hep/PLL/PDA/LM selectively inhibits the proliferation of VSMCs without affecting HUVECs. The scratch assay results indicated that Hep/PLL/PDA/LM had no significant effect on the migration ability of HUVECs (Fig. 5C–I) compared with the control group, but could significantly inhibit the migration of VSMCs (Fig. 5D–J) from 12 h. Transwell assays further demonstrated that the Hep/PLL/PDA/LM group selectively inhibited the chemotactic ability of VSMCs (Fig. 5F–L) without affecting HUVECs (Fig. 5E–K). Comprehensive scratch and transwell results show that Hep/PLL/PDA/LM does not affect the migration of HUVECs, but can specifically inhibit the migration of VSMCs. Hep/PLL/PDA/LM selectively inhibits the proliferation and migration of VSMCs. A) The colony formation of HUVECs. B) The colony formation of VSMCs. C) The scratch assay of HUVECs. D) The scratch assay of VSMCs. E) The transwell migration of HUVECs. F) The transwell migration of VSMCs. G-L) Corresponding quantitative data for the proliferation and migration of HUVECs and VSMCs: HUVECs colonies (G), VSMCs colonies (H), HUVECs scratch wound (I), VSMCs scratch wound (J), HUVECs transwell (K), VSMCs transwell (L). Data are means ± s.d. (n ≥ 3). The p-values are shown above the bars, ns: not significant, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. The selective inhibition of VSMCs’ proliferation and migration is likely mediated by the Hep coating [36]. Currently, consensus remains elusive regarding the effect of Hep on the growth of ECs. Some studies suggest that Hep inhibits the proliferation of ECs, while others report that an optimal concentration of Hep can not only improve hemocompatibility and inhibit the proliferation of VSMCs, but also promote the growth of ECs [18]. The findings of this study support the view that Hep selectively inhibits the cellular behavior of VSMCs while preserving the normal function of ECs. In summary, Hep/PLL/PDA/LM stent does not interfere with physiological endothelialization but effectively inhibits the proliferation and migration of VSMCs, thereby exerting a preventive effect against vascular restenosis at the cellular level. In vitro antioxidant and anti-inflammatory capacity AS is not only the result of dysregulated cell proliferation and migration, but also a pathological process driven by sustained oxidative stress and chronic inflammation [37]. Therefore, after clarifying the direct effects of the stent on cellular behavior, we further evaluated its ability to regulate the microenvironment of diseased blood vessels. Oxidative stress-induced reactions triggered by endothelial injury or dysfunction are highly pro-inflammatory and cytotoxic, representing a critical pathogenic step in the progression of AS [38]. Macrophages are key mediators in this process. Under conditions of oxidative stress and chronic inflammation, they drive pathological changes in ECs and VSMCs that culminate in plaque formation and vascular occlusion [39]. To evaluate the antioxidant capacity of the materials, macrophages were stimulated with hydrogen peroxide and then co-cultured with LM, PDA/LM, or Hep/PLL/PDA/LM. Intracellular ROS levels were assessed using a fluorescent probe (Fig. 6A). All treatment groups effectively scavenged ROS compared with the control (Fig. 6C). Under normal physiological conditions, NO is an important cytokine for maintaining vascular homeostasis and promotes relaxation of vascular smooth muscle. However, in pathological conditions, the bioavailability of NO is significantly reduced [40]. Excess intracellular NO reacts with superoxide to form toxic peroxynitrite, exacerbating inflammation and plaque instability [41]. After stimulating macrophages with lipopolysaccharide (LPS), co-culture with the test samples showed that LM, PDA/LM, and Hep/PLL/PDA/LM were capable of scavenging excessive NO (Fig. 6B), reducing intracellular NO levels to below 10% (Fig. 6D). To investigate the underlying mechanism of this NO reduction, we assessed the protein expression levels of iNOS and Arg-1 using western blot analysis. As shown in Fig. 6E–G, compared with the control group, the expression of iNOS in the treated cells was significantly suppressed, while Arg-1 expression was significantly elevated. These results indicate that LM, PDA/LM, and Hep/PLL/PDA/LM can scavenge intracellular excess NO by inhibiting iNOS and promoting Arg-1 expression. Antioxidant stress and anti-inflammatory capacity of Hep/PLL/PDA/LM. A) The ability to scavenge ROS. B) The ability to scavenge excess intracellular NO. C-D) The quantitative analysis of the ability to scavenge ROS and excess intracellular NO. E-G) The western blot analysis of iNOS and Arg-1. H) Immunofluorescence staining of macrophage phenotypes. I) RT-qPCR analysis of mRNA expression of relevant inflammatory factors. Data are means ± s.d. (n ≥ 6). The p-values are shown above the bars, ns: not significant, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. In the atherosclerotic microenvironment, chronic inflammatory stimulation promotes macrophage polarization toward the pro-inflammatory M1 phenotype while suppressing the anti-inflammatory M2 phenotype. Flow cytometry analysis of macrophage phenotypes (Fig. S13) showed that after treatment with LM, PDA/LM, and Hep/PLL/PDA/LM, in macrophages (usually identified by markers such as CD11b), the expression ratio of M1-type markers CD86 decreased, while the expression ratio of M2-type markers CD206 significantly increased. Further, through immunofluorescence experiments (Fig. 6H), M1 macrophages were labeled with iNOS, and M2 macrophages were labeled with CD206. The results also showed that after treatment, M1 macrophages decreased and M2 macrophages increased. In addition, reverse transcription quantitative polymerase chain reaction (RT-qPCR) analysis of key inflammatory cytokine mRNA levels demonstrated that, compared to the control group, all treatment groups exhibited reduced expression of the pro-inflammatory factors IL-1β and TNF-α, and increased expression of the anti-inflammatory factors IL-4 and IL-10. These findings provide further evidence that LM, PDA/LM, and Hep/PLL/PDA/LM possess potent anti-inflammatory and antioxidant activities (Fig. 6I). The above results indicate that LM, PDA/LM, and Hep/PLL/PDA/LM all exhibit significant antioxidant capacity, effectively suppress intracellular NO levels, and promote macrophage polarization toward the anti-inflammatory M2 phenotype, thereby exerting anti-inflammatory effects. Notably, the observed effects may be attributed to the sustained release of Ga3+ within the materials (Fig. 3C). Studies have pointed out that both Ga3+ and Ga nanoparticles possess anti-inflammatory activity: Ga3+ relies on binding to transferrin for intracellular transport, crossing the macrophage cell membrane to inhibit the production of pro-inflammatory factors [42]. While macrophages can directly take up Ga nanoparticles via endocytosis, and selectively inhibit NO synthesis and exert anti-inflammatory effects without interfering with iron homeostasis [43]. In vivo treatment of Hep/PLL/PDA/LM stent and magnetothermally regulated degradation The animal experimental procedure is illustrated in Fig. 7A. Atherosclerotic stenosis was induced in the RCCA by balloon endothelial injury followed by a high-fat diet (Fig. S14) [44]. Two months after modeling, carotid color Doppler ultrasound (Fig. 7C) revealed significant stenosis in the RCCA of the model group. The vessel diameter measured approximately 1.03 mm, representing a reduction of about 55.6% compared to the left carotid artery (2.32 mm) and confirming a diameter reduction exceeding 50%. Computed tomography angiography (CTA) examination further confirmed that, compared with the control group, the model group exhibited significant stenosis in the RCCA (Fig. 7B). Based on the typical carotid diameter range of 1.96‒2.32 mm observed in Fig. 7C, the Hep/PLL/PDA/LM stent was fabricated with a diameter of ∼2.3 mm to restore blood flow without over-dilating the vessel. The surgical implantation process is shown in Fig. 7D. Under microscopy, the RCCA was incised, revealing white atherosclerotic plaque tissue at the incision site. After the stent was implanted at the lesion site and micro-sutured, blood flow was promptly restored. CTA results confirmed that the stent was successfully implanted into the stenotic site (Fig. 7B). In vivo validation of Hep/PLL/PDA/LM stent for treating carotid artery stenosis. A) Schematic timeline of the experimental procedure (M: months). B) 3D reconstructed CTA images of rabbit carotid arteries pre-implantation, post-implantation, and 3 months post-treatment following degradation of Hep/PLL/PDA/LM stent. C) Color Doppler ultrasound evaluation of the therapeutic effect of Hep/PLL/PDA/LM. D) Procedure of stent implantation at the stenotic site. E) Magnetothermal degradation performed 3 months post-operation. F) Real-time monitoring of in vivo degradation temperature. G) Temperature profile of the surgical-side carotid artery. Data are means ± s.d. (n ≥ 6). (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.) Three months after implantation, the Hep/PLL/PDA/LM stent degradation was noninvasively triggered via an external alternating magnetic field (Fig. 7E). In vivo degradation temperature was monitored using infrared thermal imaging (Fig. 7F). Although tissue depth caused the actual temperature to exceed the surface readings, a gradual temperature rise was observed in the stent region until approximately 180 s, after which the local temperature began to decline (Fig. 7G). It suggests that the stent had likely been fully fragmented and degraded, ceasing further magnetothermal heating. Color Doppler ultrasound (Fig. 7C) results showed that the diameter of the RCCA recovered to approximately 2.04 mm after magnetothermal degradation; CTA confirmed that the stenosis of the RCCA was relieved, the blood flow was restored, and the implanted stent had been completely degraded. All rabbits in the Hep/PLL/PDA/LM magnetothermal degradation group survived during a subsequent three-month observation period. The whole-body X-ray examination (Fig. S15) revealed no significant residual stent fragments in vivo. However, whole-body radiographic imaging alone does not provide sufficient spatial resolution to exclude distal microemboli arising from small stent fragments. In addition, given the current experimental constraints, the entire degradation process could not be visualized or monitored in real time. Thus, we cannot completely rule out the possibility of microemboli that are low-incidence, transient, or below the resolution of current histological and imaging techniques. Collectively, these in vivo animal experiments demonstrate that the Hep/PLL/PDA/LM stent can effectively treat atherosclerotic plaques, inhibit postoperative restenosis, and achieve non-invasive and actively controlled degradation via external application of alternating magnetic fields. Evaluation of therapeutic efficacy for atherosclerotic vascular stenosis Systematic histological staining analysis of carotid artery tissues was performed following treatment and stent degradation. H&E staining illustrated the morphological outcomes (Fig. 8A–C). While the model group showed persistent severe luminal stenosis at the endpoint, the stent-treated group exhibited a markedly increased lumen diameter. H&E staining (Fig. S16A) showed no obvious increase in inflammatory cells at days 1 and 7 post-degradation compared with controls. CD31 is a specific marker for vascular endothelial cells. Fig. S16B revealed intact endothelium with good continuity of endothelial cells at both time points. HSP70 is a classic marker of thermal injury, with expression rising markedly within hours to days after heat exposure. Immunohistochemical staining for HSP70 (Fig. S16C and S16D) showed no appreciable positive signal at either day 1 or day 7, indicating no detectable thermal damage to the vessel wall. The combined evidence from early histological examination, HSP70 heat stress marker, and CD31 endothelial continuity supports that, under the alternating magnetic field parameters used in this study, no overt acute histological injury was detected in the carotid artery at days 1 and 7 after stent disintegration. The lumens of atherosclerotic stenotic vessels are often associated with substantial extracellular matrix and collagen deposition. In Masson staining of carotid arteries, collagen fibers appear blue. The normal arterial intima is thin with minimal collagen deposition. Masson staining (Fig. 8B–D) provided insights into extracellular matrix remodeling. The stent group, in contrast to the untreated model group, showed a restoration of orderly collagen architecture and a significant reduction in intimal thickness, both indicative of positive vascular remodeling. H&E and Masson staining were performed again 3 months after Hep/PLL/PDA/LM stent degradation (Fig. 8A–D). The results showed that even with continued high-fat diet feeding, the vessels in the stent-treated group maintained a certain degree of patency, with significantly better luminal area and intimal thickness compared to the model group. This result proved that the Hep/PLL/PDA/LM stent can effectively inhibit vascular restenosis. Histological analysis of carotid arteries. A) H&E staining. B) Masson staining. C) Carotid artery lumen diameter of H&E staining. D) Intimal thickness of Masson staining. E, F, I, and J) IHC staining for detecting the expression of relevant proteins. G, H, K, and L) Corresponding quantitative data: (G), MCP-1 expression, (H) CD14 expression, (K) α-SMA expression, (L) PCNA expression. AOD: average optical density. Data are means ± s.d. (n ≥ 6). The p-values are shown above the bars, ns: not significant, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. We next assessed key inflammatory mediators. MCP-1 initiates monocyte recruitment and differentiation into plaque macrophages [45], while CD14, expressed on these cells, amplifies inflammatory signaling and lipid uptake [46]. Compared with the model group, IHC staining of carotid arteries in Hep/PLL/PDA/LM group revealed that expressions of MCP-1 and CD14 were significantly reduced in vascular tissue after three months of treatment (Fig. 8E–H). α-SMA is a major marker of vascular smooth muscle cells: its aberrant expression reflects dynamic remodeling and dysfunction of the vascular wall cells, and overexpression can impair the endothelial barrier and accelerate plaque progression [47]. Excessive proliferation of macrophages, ECs, and VSMCs contributes to sustained inflammatory stimulation, thickening of the vascular intima, and plaque enlargement. PCNA serves as a marker of cellular proliferative activity, and its overexpression indicates active progression of atherosclerotic plaques [48]. IHC staining revealed that expressions of α-SMA and PCNA were significantly reduced following treatment with the Hep/PLL/PDA/LM stent (Fig. 8I–L). In summary, the Hep/PLL/PDA/LM stent alleviates inflammation by suppressing MCP-1 and CD14 expression, and mitigates plaque progression by suppressing α-SMA and PCNA expression, thereby effectively improving atherosclerotic stenosis, restoring carotid blood flow, and demonstrating potential for inhibiting postoperative restenosis. Discussion and conclusion At present, the stents used in clinical practice mainly include bare-metal stents and drug-eluting stents, in which antiproliferative drugs are coated onto the surface of bare-metal stents [49,50]. Bare-metal stents lack anti-inflammatory and anti-proliferative properties, leading to a high restenosis rate after implantation (17‒40%) [51,52], and their excessive mechanical strength may sometimes cause vascular injury. Drug-eluting stents, on the other hand, offer anti-restenotic effects while retaining the benefits of bare-metal stents, effectively reducing restenosis rates to 5‒10% [53]. However, the antiproliferative drugs loaded on their surface delay endothelialization to some extent, which impairs normal vascular recovery [54]. In addition, chronic inflammation associated with the permanent metallic backbone remains an unresolved issue, and the persistent presence of a metallic implant may serve as a continuing trigger for neoatherosclerosis [55]. In contrast, bioresorbable stents eliminate the sustained mechanical stimulation of a permanent implant and allow recovery of vasomotor function, thereby promoting positive remodeling, though their late restenosis rate is slightly higher than that of drug-eluting stents [8]. But the degradation process of bioresorbable stents is not easily controlled; stents that undergo premature collapse may lead to restenosis [56]. Moreover, positive remodeling itself may pose a risk-if outward vessel wall remodeling outpaces the loss of stent structural integrity, late acquired malapposition can occur, increasing the risk of late stent thrombosis [57]. LM has recently been investigated as a functional electrode material integrated onto conventional stents for sensing, monitoring, and therapeutic applications [58]. Its advantages over rigid electrodes include high conductivity, good stretchability, and better compliance with vessel dynamics. Separately, gallium-indium LM has been used to induce embrittlement and on-demand fragmentation of aluminum-based devices in vivo [11]—but in that case, LM serves as a degradation trigger rather than a structural scaffold. In our design, the liquid metal is first solidified into the stent backbone to supply radial support, coated with Hep for antithrombotic function, and then capable of being actively heated and degraded in response to an alternating magnetic field. Unlike current biodegradable metal stents, the advantage of our stent lies not in superior mechanical performance, but in combining temporary mechanical support with active post-treatment removal within a single system. Traditional metal stents, though strong, remain permanently in the vessel; persistent foreign-body stimulation may contribute to late thrombosis, chronic inflammation, and restenosis. In contrast, the Hep/PLL/PDA/LM stent remains stable during vascular remodeling and, after support is no longer needed, can be triggered by an external alternating magnetic field to undergo solid-liquid phase transition and structural disintegration, thereby allowing active control over its residence time. The Hep/PLL/PDA/LM stent differs from magnesium-based (natural corrosion) and iron-based (coating-induced acid erosion) stents in that it enables external control over degradation timing and rate, and retains stable radial support without a magnetic field. This active controllability is a key innovation that, in theory, could be used alongside imaging and clinical monitoring to avoid restenosis and stent thrombosis. In summary, this study reported the first development of a LM stent with magnetothermal responsiveness, for treating AS-induced vascular stenosis. Upon implantation in a rabbit carotid artery stenosis model, the stent provided sufficient radial support for effective vascular expansion. The incorporated Hep coating not only conferred significant anti-thrombogenic capacity but also specifically inhibited the proliferation and migration of VSMCs, thereby exerting the anti-restenotic effect. Importantly, Ga, as one of the principal components of the stent matrix, itself possesses strong anti-inflammatory activity and contributes directly to the therapeutic effect against AS. Compared with existing self-degradable and conventional vascular stents, the Hep/PLL/PDA/LM stent offers three key advantages: (1) precise customization based on patient anatomy; (2) mechanical properties comparable to traditional stent materials; and (3) the unique capability for non-invasive, on-demand degradation via external application of an alternating magnetic field, thereby avoiding long-term implant complications and eliminating the need for secondary surgical extraction. As a preliminary investigation, this study has several limitations. First, while in vitro degradation produced tiny fragments (<0.5 mm), the risk of micro-fragment embolization in small-caliber vessels cannot be entirely excluded. Even though the whole-body X-ray detected no residual fragments, the potential for micro-embolization in small-caliber vasculature remains a concern. Second, the in vivo degradation process cannot be directly visualized. Indirect monitoring via surface thermography may underestimate actual stent temperature, and precise control of the degradation rate remains challenging. Third, the current stents lack the structural integrity and surface finish of commercial stents and are not yet suitable for catheter-based delivery, limiting immediate clinical translation. In view of the innovative concepts of “precise personalized customization” and “actively controlled non-invasive degradation”, the proposed LM-based device holds great potential for broader and deeper application in future research across areas, such as inferior vena cava filters, bone implant repair materials, esophageal stents, and brain-machine interface materials. CRediT authorship contribution statement Jianxiang Xiong: Data curation, Formal analysis, Investigation, Methodology, Validation, Writing – original draft, Writing – review & editing. Li Huang: Data curation, Investigation, Validation. Jingzheng Huang: Methodology, Resources. Zhibin Zhou: Methodology, Resources, Supervision. Shen Hu: Methodology, Resources. Wenpeng Zhao: Writing – review & editing. Guizhen Xu: Resources, Supervision. Xingchun Lai: Resources. Guoyu Yang: Supervision, Writing – review & editing. Weimin Zhou: Funding acquisition, Resources. Xiaolei Wang: Funding acquisition, Resources, Supervision, Writing – review & editing. Ethics approval statement All animals used in this study were obtained from the Laboratory Animal Science Center of Nanchang University. All experimental procedures were approved by the Animal Ethics Committee of Nanchang University (NCULAE-20221228026) and conducted in strict accordance with the Guide for the Care and Use of Laboratory Animals issued by the National Institutes of Health. Funding statement This work was funded by the National Natural Science Foundation of China (No. 32560229 to X.W; No. 82460103 to W.Z; No. 82500593 to L.H), Interdiscipline Innovation Fund Project of Nanchang University (PYJX20230001 to X.W), Jiangxi Province Key Laboratory of bioengineering drugs (No.2024SSY07061 to X.W), Key Science and Technology Innovation Project of Jiangxi Provincial Health Commission (Grant No. 2024ZD005 to W.Z), and the Second Affiliated Hospital of Nanchang University Funding Program (2023efyA02 to W.Z). Declaration of competing interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Acknowledgements Not applicable. Footnotes Supplementary data to this article can be found online at https://doi.org/10.1016/j.mtbio.2026.103561. Contributor Information Guoyu Yang, Email: yangguoyu@ncu.edu.cn. Weimin Zhou, Email: drzwm@sina.com. Xiaolei Wang, Email: wangxiaolei@ncu.edu.cn. Supplementary data The following is/are the supplementary data to this article: Multimedia component 1 Data availability Data will be made available on request. References Associated Data Supplementary Materials Multimedia component 1 Data Availability Statement Data will be made available on request.